- Market News
Novel transfection reagent set to alleviate viral vector bottleneck7 Apr 2020
The FectoVIR-AAV transfection reagent achieves large-scale transient transfection resulting in up to a 10-fold increase in AAV functional viral titer yields in suspension cell systems.
Polyplus-transfection, a biotechnology company that supplies the gene and cell therapy market with innovative transfection solutions, will make available to the market a novel transfection reagent FectoVIR-AAV in May 2020.
The reagent has been specifically developed to improve AAV (adeno-associated virus) production in suspension cell culture system for large-scale manufacturing.
AAVs are predominantly used in gene therapy development. To date, there has been a significant and well-identified bottleneck in manufacturing sufficient amounts of AAV viral vectors to treat patients. This will continue to increase as more therapies are commercialized and reach late-stage clinical trials.
To increase capabilities, viral manufacturers are looking for effective ways to adapt key steps of production for large-scale manufacturing. Transient transfection is a critical step that is indispensable for a reliable industrial manufacturing process. Polyplus-transfection has developed the FectoVIR-AAV transfection reagent to achieve large-scale transient transfection resulting in up to a 10-fold increase in AAV functional viral titer yields in suspension cell systems.
Polyplus-transfection developed the FectoVIR-AAV transfection reagent in partnership with a range of viral manufacturers internationally. Rather than follow the industry standard model of developing a reagent for small-scale manufacturing and adapting for large-scale production, Polyplus-transfection has developed the entirely new reagent with large-scale transient transfection in mind, and then validated its use all the way through the R&D process.
“The AAV viral vector bottleneck has been persistently identified as a major challenge for the development of the entire gene therapy industry,” said Karsten Wilking, CEO, Polyplus-transfection. Yet, by working with a range of handpicked international viral manufacturers to provide the FectoVIR-AAV reagent, the company has helped to alleviate a major concern for the gene therapy sector and will result in a high number of therapies reaching the market and patients more quickly.
Are you a supplier
Here's what we can do for you
- Generate quality leads for your business
- Stay visible for 365 days of the year
- Receive product inquiries and respond to meeting requests directly
- Improve company online presence through Search Engine Optimisation